Mechanism of STMN2 cryptic splice-polyadenylation and its correction for TDP-43 proteinopathies.

Journal: Science (New York, N.Y.)
Published:
Abstract

Loss of nuclear TDP-43 is a hallmark of neurodegeneration in TDP-43 proteinopathies, including amyotrophic lateral sclerosis (ALS) and frontotemporal dementia (FTD). TDP-43 mislocalization results in cryptic splicing and polyadenylation of pre-messenger RNAs (pre-mRNAs) encoding stathmin-2 (also known as SCG10), a protein that is required for axonal regeneration. We found that TDP-43 binding to a GU-rich region sterically blocked recognition of the cryptic 3' splice site in STMN2 pre-mRNA. Targeting dCasRx or antisense oligonucleotides (ASOs) suppressed cryptic splicing, which restored axonal regeneration and stathmin-2-dependent lysosome trafficking in TDP-43-deficient human motor neurons. In mice that were gene-edited to contain human STMN2 cryptic splice-polyadenylation sequences, ASO injection into cerebral spinal fluid successfully corrected Stmn2 pre-mRNA misprocessing and restored stathmin-2 expression levels independently of TDP-43 binding.

Authors
Michael Baughn, Ze'ev Melamed, Jone López Erauskin, Melinda Beccari, Karen Ling, Aamir Zuberi, Maximilliano Presa, Elena Gonzalo Gil, Roy Maimon, Sonia Vazquez Sanchez, Som Chaturvedi, Mariana Bravo Hernández, Vanessa Taupin, Stephen Moore, Jonathan Artates, Eitan Acks, I Ndayambaje, Ana Agra De Almeida Quadros, Paayman Jafar Nejad, Frank Rigo, C Bennett, Cathleen Lutz, Clotilde Lagier Tourenne, Don Cleveland